PD1+TIGIT+2B4+KLRG1+ Cells Might Underlie T Cell Dysfunction in Patients Treated with BCMA-Directed Chimeric Antigen Receptor T Cell Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PD1+TIGIT+2B4+KLRG1+ Cells Might Underlie T Cell Dysfunction in Patients Treated with BCMA-Directed Chimeric Antigen Receptor T Cell Therapy

Published:2024-02 Issue:2 Volume:30 Page:191-202
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Mishra Ameet K.,Schmidt Timothy M.,Martell Ella B.,Chen Alex S.,Dogru Reyna E.,Hematti Peiman,Callander Natalie S.

Funder

University of Wisconsin-Madison Carbone Cancer Center

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference40 articles.

1. Idecabtagene vicleucel in relapsed and refractory multiple myeloma;Munshi;N Engl J Med,2021

2. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study;Berdeja;Lancet,2021

3. Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice;Gajra;Pharmaceut Med,2022

4. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies;Xu;Front Immunol,2019

5. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma;Vercellino;Blood Adv,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific antibodies in the treatment of multiple myeloma;Blood Cancer Journal;2024-09-12

2. CAR-T Therapy in Multiple Myeloma: Looking Beyond;Hemato;2024-05-31

3. Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy;Expert Review of Clinical Immunology;2024-05-14

4. CARving a Path Forward: Unveiling T Cell Phenotypes Across the Spectrum of Multiple Myeloma Disease Progression to Inform Future Strategies for Overcoming Resistance to CAR T Therapy;Transplantation and Cellular Therapy;2024-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3